← All trials
NCT06650605
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Apr 30, 2027
- First posted
- Oct 21, 2024
- Last posted
- Oct 21, 2024
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Theragnostics LtdLead sponsor
- University of LondonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.